Skip to content

Neoadjuvant pembrolizumab in high-risk thyroid cancers (NEPENTHE)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-519129-38-00
Enrollment
25
Registered
2025-01-13
Start date
2023-10-25
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

thyroid cancers

Brief summary

To investigate the behavior of exhausted CD8+ T in response to pembrolizumab in TCs and the relationships between T cell clusters. To this aim, “spatial-transcriptomic” sequencing will be performed in tumor tissues and will be paired to single-cell maps at peripheral level before and after pembrolizumab.

Detailed description

Cancer immunotherapy aims to induce a durable human immune response in order to destroy tumour cells (Jacobson M, 2019). Biological mechanisms behind a prolonged immune response are still unknown. We hypothesize that the persistence of tumor-specific T-cell clones after the treatment of primary cancer, might contribute to a durable immune response as well as a better patients’ outcome. Single cell/spatial-transcriptomics sequencing will be applied to the blood samples collected after surgery and

Interventions

DRUGKEYTRUDA 25 mg/mL concentrate for solution for infusion

Sponsors

Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
To investigate the behavior of exhausted CD8+ T in response to pembrolizumab in TCs and the relationships between T cell clusters. To this aim, “spatial-transcriptomic” sequencing will be performed in tumor tissues and will be paired to single-cell maps at peripheral level before and after pembrolizumab.

Secondary

MeasureTime frame
Cancer immunotherapy aims to induce a durable human immune response in order to destroy tumour cells (Jacobson M, 2019). Biological mechanisms behind a prolonged immune response are still unknown. We hypothesize that the persistence of tumor-specific T-cell clones after the treatment of primary cancer, might contribute to a durable immune response as well as a better patients’ outcome. Single cell/spatial-transcriptomics sequencing will be applied to the blood samples collected after surgery and

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026